🔎 Trials Near Me

Hjem › Akut myelogen leukemi › Connecticut › New Haven

Kliniske studier for Akut myelogen leukemi i New Haven, CT

17 studier for Akut myelogen leukemi søker deltakere på steder i og rundt New Haven (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • Yale University, New Haven
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564390

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

RekruttererFase 1
  • Yale University, New Haven
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06484062

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Yale University, New Haven
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Yale University, New Haven
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • Yale University, New Haven
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • Yale University, New Haven
29 Days – 21 Years · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RekruttererFase 3
  • Yale University School of Medicine, New Haven
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RekruttererFase 1
  • Smilow Cancer Hospital at Yale New Haven, New Haven
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

RekruttererFase 1
  • Yale University, Yale Cancer Center, New Haven
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06656494

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekruttererObservasjonsstudie
  • Yale New Haven Hospital, New Haven
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

RekruttererFase 1
  • Yale New Haven Hospital, New Haven
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jun. 2026 · NCT05768932

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

RekruttererFase 2/3
  • Yale University, New Haven
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT04256317

Revumenib in Combination With 7+3 + Midostaurin in AML

RekruttererFase 1
  • Yale Cancer Center, New Haven
Alder 18 til 75 · Alle kjønn · Oppdatert 25. mar. 2026 · NCT06313437

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RekruttererFase 1
  • Yale Cancer Center and Smilow Cancer Hospital, New Haven
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

RekruttererFase 1/2
  • Yale University, New Haven
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2025 · NCT03850574

Akut myelogen leukemi-studier i andre byer

Andre studier i New Haven

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.